Have a personal or library account? Click to login
Re-Irradiation in Squamous Cell Carcinoma of the Head and Neck Cover

Re-Irradiation in Squamous Cell Carcinoma of the Head and Neck

Open Access
|Oct 2023

Figures & Tables

Figure 1:

Survival function using Kaplan-Meier estimates following re-irradiation for patients with recurrent/second primary head and neck cancer.
Survival function using Kaplan-Meier estimates following re-irradiation for patients with recurrent/second primary head and neck cancer.

Figure 2:

Locoregional recurrence using Kaplan-Meier estimates following re-irradiation for patients with recurrent/second primary head and neck cancer.
Locoregional recurrence using Kaplan-Meier estimates following re-irradiation for patients with recurrent/second primary head and neck cancer.

Stratification of overall survival (OS) groups at 2 years resulting from multivariate analysis (3)_

Class ITreatment interval > 2 years, in patients submitted to surgery2 years OS of 62%
Class IITreatment interval > 2 years, in patients not submitted to surgery or interval < 2 years, without organ dysfunction2 years OS of 40%
Class IIIInterval between treatments < 2 years, with organ dysfunction2 years OS of 17%

Toxicity grading differences between first and second irradiation_

Toxicity gradeTiming, % (n)Time between irradiations (months), median (IQR)

After first irradiationAfter re-irradiation
Dermatitis
159.0 (23)59.0 (23)21.0 (47)
233.3 (13)30.8 (12)31.0 (41)
37.7 (3)10.3 (4)24.5 (19)
Mucositis
035.9 (14)33.3 (13)20.0 (14)
117.9 (7)35.9 (14)26.0 (47)
233.3 (13)12.8 (5)39.0 (109)
312.8 (5)17.9 (7)24.0 (89)
Xerostomia
023.1 (9)5.1 (2)34.0
146.2 (18)76.9 (30)21.0 (36)
230.8 (12)17.9 (7)27.0 (92)
Dysphagia
033.3 (13)20.5 (8)26.0 (117)
117.9 (7)35.9 (14)23.0 (46)
217.9 (7)15.4 (6)21.0 (25)
330.8 (12)28.2 (11)16.0 (35)

Univariate logistic regression of predictors for severe toxicity after first and second irradiations_

VariablesAfter first irradiationAfter re-irradiation

RR (CI 95%)P-valueRR (CI 95%)P-value
Location (reference: oropharynx)
Oral cavity0.93 (0.11–7.82).949--
Nasopharynx4.20 (0.33–53.1).2680.24 (0.02–3.01).268
Larynx0.70 (0.13–3.68).2680.51 (0.10–2.59).416
Hypopharynx0.93 (0.11–7.82).9490.48 (0.06–4.00).494
ECOG status (reference: 0)
15,08 (0,48–54,03).1781.40 (0.35–5.54).632
2--3.60 (0.32–40.23).298
CT cycles (per each cycle)1.27 (0.74–2.17).3830.97 (0.51–1.84).933
Dose of RT (per each Gy)0.98 (0.84–1.14).7801.06 (0.98–1.13).134
Concurrent chemotherapy3.90 (0.96–15.82).0571.25 (0.28–5.59).770

Disease features at first and second radiotherapy irradiation_

VariableTiming, % (n)

At first irradiationAt re-irradiation
Location
Oropharynx30.8 (12)
Oral cavity12.8 (5)
Nasopharynx10.3 (4)
Larynx30.8 (12)
Hypopharynx12.8 (5)
Others2.6 (1)
ECOG Performance status
089.7 (35)56.4 (22)
110.3 (4)33.3 (13)
20.0 (0)10.3 (4)
T-stage
T05.1 (2)20.5. (8)
T133.3 (13)5.1 (2)
T215.4 (6)23.1 (9)
T317.9 (7)12.8 (5)
T428.2 (11)38.5 (15)
N-stage
N041.0 (16)53.8 (21)
N123.1 (9)15.4 (6)
N228.2 (11)20.5 (8)
N37.7 (3)10.3 (4)
M-stage
M0100.0 (39)94.9 (37)
M10.0 (0)5.1 (2)
Clinical stage
I20.5 (8)5.1 (2)
II12.8 (5)15.4 (6)
III15.4 (6)15.4 (6)
IV51.3 (20)64.1 (25)
CT cycles, median (IQR)2.0 (2)0.0 (0)
Dose of RT (Gy), median (IQR)70.0 (4.0)60.0 (16)
Concurrent chemotherapy56.4 (22)23.1 (9)

Concurrent chemotherapy (cCT) and toxicity grading following first and second irradiation_

Toxicity gradeAfter first irradiationAfter re-irradiation

cCTWithout cCTcCTWithout cCT
Dermatitis
150.0 (11)70.6 (12)44.4 (4)63.3 (19)
240.9 (9)23.5 (4)44.4 (4)26.7 (8)
39.1 (2)5.9 (1)11.1 (1)10.0 (3)
Mucositis
027.3 (6)47.1 (8)22.2 (2)36.7 (11)
118.2 (4)17.6 (3)33.3 (3)36.7 (11)
236.4 (8)29.4 (5)22.2 (2)10.0 (3)
318.2 (4)5.9 (1)22.2 (2)16.7 (5)
Xerostomia
013.6 (3)35.3 (6)0.0 (0)6.7 (2)
150.0 (11)41.2 (7)77.8 (7)76.7 (23)
236.4 (8)23.5 (4)22.2 (2)16.7 (5)
Dysphagia
022.7 (5)a47.1 (8)a22.2 (2)20.0 (6)
19.1 (2)a29.4 (5)a33.3 (3)36.7 (11)
227.3 (6)a5.9 (1)a22.2 (2)13.3 (4)
340.9 (9)a17.6 (3)a22.2 (2)30.0 (9)
DOI: https://doi.org/10.2478/fco-2023-0002 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Language: English
Page range: 40 - 48
Submitted on: Dec 17, 2022
Accepted on: Mar 1, 2023
Published on: Oct 11, 2023
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2023 João Barros, Mónica Rodrigues, Regina Leite, David Rothwell, Beatriz Pires, Tânia Serra, Leila Khouri, Paula Alves, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.